文献速递前列腺癌

亚洲前列腺癌流行病学与治疗模式的演变:全球视角

Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia.
PubMed 文献 · BJU Int · 2025-08-24

本综述分析了亚洲泌尿外科学会成员国的前列腺癌流行病学、临床特征、药物疗效与安全性、治疗及检测普及率以及生存趋势。亚洲男性初诊时更具侵袭性,但生存结局反而常优于白人;发展中国家死亡率上升,主要因筛查可及性有限和医疗基础设施差异。5年生存率与人均GDP正相关,经济与卫生政策仍是亚洲前列腺癌结局的关键决定因素。

要点

  • 亚洲男性前列腺癌初诊更具侵袭性,但生存结局常优于白人。
  • 发展中国家前列腺癌死亡率持续上升,筛查可及性有限是主因。
  • 5年生存率与人均GDP正相关,经济与政策影响预后。

核心结论

  • 亚洲发达国家与发展中国家在前列腺癌死亡率与发病率比值、PSA筛查覆盖率、新疗法可及性和报销政策方面存在显著差异。
  • 尽管医学进步,经济状况和卫生政策基础设施仍是亚洲前列腺癌结局的关键决定因素。
  • 5年生存率与人均GDP的相关性分析凸显了后者对前列腺癌预后的巨大影响。

研究设计与样本

  • 本综述分析了亚洲泌尿外科学会成员国的前列腺癌流行病学、临床特征、治疗药物疗效与安全性、治疗及检测普及率以及生存趋势。
  • 研究使用了GLOBOCAN 2022版最新数据、CONCORD-3研究数据和国际货币基金组织数据库来调查发病率、死亡率和生存率的地区差异。

主要发现

  • 亚洲男性与白人相比倾向于表现为更具侵袭性的前列腺癌。
  • paradoxically,尽管亚洲人群疾病更具侵袭性,但生存结局往往更好。
  • 根据GLOBOCAN 2022数据,前列腺癌发病率在北美、大洋洲和欧洲最高,而亚洲国家发病率和死亡率最低,但亚洲各国间差异显著。
  • 许多发展中亚洲国家前列腺癌死亡率持续上升,主要因前列腺癌筛查可及性有限和医疗基础设施差异。
  • 亚洲人群前列腺癌治疗有效性可与全球试验相当,但亚太地区治疗可及性差异很大。

临床怎么用

  • 临床应关注亚洲男性前列腺癌更具侵袭性的特点,初诊时需更积极评估。
  • 在发展中国家,应重视提高前列腺癌筛查可及性和医疗基础设施建设以改善结局。
  • 治疗决策需考虑当地药物可及性和报销政策差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There are notable regional differences in the incidence and mortality of prostate cancer (PCa), whose underlying causes are arguably complex and multifactorial. In this review, we analysed the epidemiology, clinical characteristics, efficacy and safety of therapeutic drugs, prevalence of treatment and testing, and trends in PCa survival in Asian Urological Association member countries. METHODS: To investigate regional differences in incidence, mortality, and survival, we used the latest data from the GLOBOCAN 2022 edition, CONCORD-3 study data, and the International Monetary Fund database. RESULTS: Asian men tend to present with more aggressive forms of PCa than their Caucasian counterparts. Paradoxically, survival outcomes are often better in Asian populations despite their more aggressive disease profiles. According to the GLOBOCAN 2022 data, PCa incidence is the highest in North America, Oceania, and Europe, but the lowest in incidence and mortality in Asian countries, despite varying significantly across these countries. Many developing Asian countries continue to experience rising mortality rates from PCa, largely due to limited access to PCa screening and disparities in healthcare infrastructure. While PCa treatments demonstrate comparable effectiveness in Asian populations to that in global trials, access to these therapies remains highly variable across the Asia-Pacific region, highlighting the need for access to improved healthcare policies and systems. In developing Asian nations, the 5-year survival rate (5Y-SR) is shown to be positively correlated with gross domestic product (GDP) per capita, suggesting that economic factors play a key determinant in PCa outcomes in these regions. CONCLUSIONS: Our analysis reveals stark disparities between developed and developing Asian countries, particularly in mortality-to-incidence ratios, prostate-specific antigen screening coverage, access to novel therapeutics, and reimbursement policies. Despite medical advances, economic status and health policy infrastructure remain key determinants of PCa outcomes in Asia. Moreover, our analysis of 5Y-SR relative to GDP per capita underscores the colossal impact of the latter on PCa prognosis.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ito K, Mori K, Kumar R, et al. Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia. BJU Int. 2025. PMID: 40851349. doi:10.1111/bju.16900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。